# GEN - Project

> **NIH NIH P30** · UNIVERSITY OF VIRGINIA · 2024 · $27,846

## Abstract

MOLECULAR GENETICS AND EPIGENETICS (GEN) – PROJECT SUMMARY/ABSTRACT
 The accumulation of heritable genetic and epigenetic changes that result in the loss of tumor suppressors
and/or inappropriate activation of proto-oncogenes is a hallmark of cancer. The goals of the Molecular
Genetics and Epigenetics Program (GEN) are to understand the molecular mechanisms that underlie these
defects and to unleash the potential of precision medicine. The Program capitalizes on the large number of
outstanding investigators at UVA with research expertise in chromatin architecture, transcription, replication,
DNA repair, genomics, epigenomics and cellular checkpoints in cancer. The Members are organized around
three main themes: (1) chromosome function, malfunction, and cellular checkpoints; (2) changes to gene
expression and epigenetics that drive cancer; and (3) cancer bioinformatics. H. Li and Stukenberg bring
complementary clinical/translational and fundamental biological expertise to lead GEN. The Program has 24
current members from one school and seven departments. Eight of these individuals are new to the Program
or to UVA since the last renewal. They bring considerable expertise in the bioinformatics of microarray and
deep-sequencing data, large-scale genomic rearrangements, the molecular effects of and cellular responses to
radiation, computational biology, and epigenetics, maintaining our strength in that area. Program Members are
principal investigators of grants totaling $5.04M of direct cost peer-reviewed funding, of which $1.55M is from
NCI and $3.49M from other peer-reviewed sources. GEN Members rely on infrastructure provided by the
UVACC, particularly the Advance Microscopy Facility, Flow Cytometry Core, and the Molecular and
Immunological Translational Science Core. GEN is composed of highly productive and collaborative members
with 169 selected publications since the last grant period. Of these, 40% have an impact factor of 10 or
greater, 27% are intra-programmatic, 22% are inter-programmatic with other UVACC Programs, and 20% are
collaborative with other NCI Cancer Centers.

## Key facts

- **NIH application ID:** 10766145
- **Project number:** 5P30CA044579-33
- **Recipient organization:** UNIVERSITY OF VIRGINIA
- **Principal Investigator:** P. TODD STUKENBERG
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $27,846
- **Award type:** 5
- **Project period:** 1997-09-16 → 2027-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10766145

## Citation

> US National Institutes of Health, RePORTER application 10766145, GEN - Project (5P30CA044579-33). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10766145. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*